Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC
Authors:
- Thomas MuleyTMThomas Muley
- Timea-Helene FetzTFTimea-Helene Fetz
- Hendrik DienemannHDHendrik Dienemann
- Hans HoffmannHHHans Hoffmann
- Felix J.F. HerthFHFelix J.F. Herth
- Michael MeisterMMMichael Meister
- Werner EbertWEWerner Ebert
- 1 June 2008
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 60 (3) , 408-415
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Gene Expression Signature Predicts Recurrence in Lung AdenocarcinomaClinical Cancer Research, 2007
- Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in 143 Phase III TrialsJournal of Thoracic Oncology, 2007
- The Rationale for Adjuvant Chemotherapy in Stage I Non-small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Genomic and Proteomic Profiling of Lung Cancers: Lung Cancer Classification in the Age of Targeted TherapyJournal of Clinical Oncology, 2005
- A molecular signature of metastasis in primary solid tumorsNature Genetics, 2002
- Expression profiling of primary non-small cell lung cancer for target identificationOncogene, 2002
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002
- Prognostic factors in clinical stage I non–small cell lung cancerThe Annals of Thoracic Surgery, 1999
- 717 Preoperative CYFRA21-1 levels as a prognostic indicator in resected non-small cell lung cancer (NSCLC)Lung Cancer, 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958